Pharmacogenomics of blood pressure response to antihypertensive treatment

Journal of Hypertension

Volumn 23, Issue 7, 2005, Pages 1311-1325

  Mellen, Philip B ^a   Herrington, David M ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Antihypertensive agents; Hypertension; Pharmacogenetics

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CANDESARTAN; CAPTOPRIL; CYTOCHROME P450; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FOSINOPRIL; HYDROCHLOROTHIAZIDE; IRBESARTAN; METOPROLOL; PERINDOPRIL;

ANTIHYPERTENSIVE ACTIVITY; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; DRUG ACTIVITY; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; HYPERTENSION; NONHUMAN; PHARMACOGENOMICS; PRIORITY JOURNAL; SYSTEMATIC REVIEW;

EID: 21644466324     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.hjh.0000173510.52987.68     Document Type: Article

References (109)

1. Fields LE, Burt VL, Cutler JA, Hughes J, Roccella EJ, Sorlie P. The burden of adult hypertension in the United States 1999 to 2000. A rising tide. Hypertension 2004; 44:398-404.
2. Murray C, Lopez A. World Health Report 2002, reducing risks, promoting healthy life. Geneva: World Health Organization; 2002.
3. Fischer MA, Avorn J. Economic implications of evidence-based prescribing for hypertension: can better care cost less? JAMA 2004; 291:1850-1856.
4. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288:2981-2997.
5. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42:1206-1252.
6. Materson BJ. Variability in response to antihypertensive drug treatment. Hypertension 2004; 43:1166-1167.
7. Materson BJ, Reda DJ, Cushman WC, Massie BM, Freis ED, Kochar MS, et al. Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. N Engl J Med 1993; 328:914-921.
8. Preston RA, Materson BJ, Reda DJ, Williams DW, Hamburger RJ, Cushman WC, et al. Age-race subgroup compared with renin profile as predictors of blood pressure response to antihypertensive therapy. JAMA 1998; 280:1168-1172.
9. Laragh JH, Lamport B, Sealey J, Alderman MH. Diagnosis ex juvantibus. Individual response patterns to drugs reveal hypertension mechanisms and simplify treatment. Hypertension 1988; 12:223-226.
10. Lind L, Berne C, Andersson PE, Hanni A, Lithell H. Is insulin resistance a predictor or the blood pressure response to anti-hypertensive treatment? J Hum Hypertens 1995; 9:759-763.
11. Venter JC, Adams MD, Myers EW, Li PW, Mural RJ, Sutton GG, et al. The sequence of the human genome. Science 2001; 291:1304-1351.
12. Luft FC. Geneticism of essential hypertension. Hypertension 2004; 43:1155-1159.
13. Lifton RP, Gharavi AG, Geller DS. Molecular mechanisms of human hypertension. Cell 2001; 104:545-556.
14. Pharmacogenetics. Stedman's Electronic Medical Dictionary. Lippincott Williams & Wilkins; 2004 [http://www.stedmans.com/section.cfm/45].
15. Pickering G. Systemic arterial hypertension. In: Fishman AP, Richards DW (editors): Circulation of the blood: men and ideas. Bethesda, MD: American Physiological Society; 1964, pp. 487-544.
16. Weinshilboum R. Inheritance and drug response. N Engl J Med 2003; 348:529-537.
17. Lima JJ, Thomason DB, Mohamed MH, Eberle LV, Self TH, Johnson JA. Impact of genetic polymorphisms of the beta2-adrenergic receptor on albuterol bronchodilator pharmacodynamics. Clin Pharmacol Ther 1999; 65:519-525.
18. Israel E, Drazen JM, Liggett SB, Boushey HA, Cherniack RM, Chinchilli VM, et al. Effect of polymorphism of the beta(2)-adrenergic receptor on response to regular use of albuterol in asthma. Int Arch Allergy Immunol 2001; 124:183-186.
19. Evans WE, McLeod HL. Pharmacogenomics - drug disposition, drug targets, and side effects. N Engl J Med 2003; 348:538-549.
20. Gonzalez FJ, Skoda RC, Kimura S, Umeno M, Zanger UM, Nebert DW, et al. Characterization of the common genetic defect in humans deficient in debrisoquine metabolism. Nature 1988; 331:442-446.
21. Shah RR, Oates NS, Idle JR, Smith RL. Beta blockers and drug oxidation status. Lancet 1982; 1:1019-1020.
22. Uetrecht JP, Woosley RL. Acetylator phenotype and lupus erythematosus. Clin Pharmacokinet 1981; 6:118-134.
23. Campbell NR, Dunnette JH, Mwaluko G, Van Loon J, Weinshilboum RM. Platelet phenol sulfotransferase and erythrocyte catechol-O-methyltransferase activities: correlation with methyldopa metabolism. Clin Pharmacol Ther 1984; 35:55-63.
24. Luft FC, Weinberger MH. Heterogeneous responses to changes in dietary salt intake: the salt-sensitivity paradigm. Am J Clin Nutr 1997; 65(2 Suppl):612S-617S
25. Beeks E, Kessels AG, Kroon AA, van der Klauw MM, de Leeuw PW. Genetic predisposition to salt-sensitivity: a systematic review. J Hypertens 2004; 22:1243-1249.
26. Tripodi G, Valtorta F, Torielli L, Chieregatti E, Salardi S, Trusolino L, et al. Hypertension-associated point mutations in the adducin alpha and beta subunits affect actin cytoskeleton and ion transport. J Clin Invest 1996; 97:2815-2822.
27. Manunta P, Burnier M, D'Amico M, Buzzi L, Maillard M, Barlassina C, et al. Adducin polymorphism affects renal proximal tubule reabsorption in hypertension. Hypertension 1999; 33:694-697.
28. Cusi D, Barlassina C, Azzani T, Casari G, Citterio L, Devoto M, et al. Polymorphisms of α-adducin and salt sensitivity in patients with essential hypertension. The Lancet 1997; 349:1353-1357.
29. Barlassina C, Schork NJ, Manunta P, Citterio L, Sciarrone M, Lanella G, et al. Synergistic effect of alpha-adducin and ACE genes causes blood pressure changes with body sodium and volume expansion. Kidney Int 2000; 57:1083-1090.
30. Manunta P, Cusi D, Barlassina C, Righetti M, Lanzani C, D'Amico M, et al. α-Adducin polymorphisms and renal sodium handling in essential hypertensive patients. Kidney Int 1998; 53:1471-1478.
31. Sciarrone MT, Stella P, Barlassina C, Manunta P, Lanzani C, Bianchi G, et al. ACE and α-adducin polymorphism as markers of individual response to diuretic therapy. Hypertension 2003; 41:398-403.
32. Glorioso N, Manunta P, Filigheddu F, Troffa C, Stella P, Barlassina C, et al. The role of α-adducin polymorphism in blood pressure and sodium handling regulation may not be excluded by a negative association study. Hypertension 1999; 34:649-654.
33. Grant FD, Romero JR, Jeunemaitre X, Hunt SC, Hopkins PN, Hollenberg NH, et al. Low-renin hypertension, altered sodium homeostasis, and an α-adducin polymorphism. Hypertension 2002; 39:191-196.
34. Winnicki M, Somers VK, Accurso V, Hoffmann M, Pawlowski R, Frigo G, et al. α-Adducin Gly460Trp polymorphism, left ventricular mass and plasma renin activity. J Hypertens 2002; 20:1771-1777.
35. Castejon AM, Alfieri AB, Hoffmann IS, Rathinavelu A, Cubeddu LX. Alpha-adducin polymorphism, salt sensitivity, nitric oxide excretion, and cardiovascular risk factors in normotensive hispanics. Am J Hypertens 2003; 16:1018-1024.
36. Ciechanowicz A, Widecka K, Drozd R, Adler G, Cyrylowski L, Czekalski S. Lack of association between Gly460Trp polymorphism of alpha-adducin gene and salt sensitivity of blood pressure in Polish hypertensives. Kidney Blood Press Res 2001; 24:201-206.
37. Turner ST, Chapman AB, Schwartz GL, Boerwinkle E. Effects of endothelial nitric oxide synthase, α-adducin, and other candidate gene polymorphisms on blood pressure response to hydrochlorothiazide. Am J Hypertens 2003; 16:834-839.
38. Brand E, Schorr U, Ringel J, Beige J, Distler A, Sharma AM. Aldosterone synthase gene (CYP11B2) C-344T polymorphism in Caucasians from the Berlin Salt-Sensitivity Trial (BeSST). J Hypertens 1999; 17:1563-1567.
39. Poch E, Gonzalez D, Giner V, Bragulat E, Coca A, de la SA. Molecular basis of salt sensitivity in human hypertension. Evaluation of renin-angiotensin-aldosterone system gene polymorphisms. Hypertension 2001; 38:1204-1209.
40. Pamies-Andreu E, Ramirez-Lorca R, Stiefel Garcia-Junco P, Muniz-Grijalbo O, Vallejo-Maroto I, Garcia MS, et al. Renin-angiotensin-aldosterone system and G-protein beta-3 subunit gene polymorphisms in salt-sensitive essential hypertension. J Hum Hypertens 2003; 17: 187-191.
41. Poch E, Gonzalez D, de la SA, Giner V, Bragulat E, Botey A, et al. Genetic variation of the gamma subunit of the epithelial Na+ channel and essential hypertension. Relationship with salt sensitivity. Am J Hypertens 2000; 13:648-653.
42. Schorr U, Beige J, Ringel J, Turan S, Kreutz R, Distler A, et al. Hpa II polymorphism of the atrial natriuretic peptide gene and the blood pressure response to salt intake in normotensive men. J Hypertens 1997; 15: 715-718.
43. Lovati E, Ferrari P, Dick B, Jostarndt K, Frey BM, Frey FJ, et al. Molecular basis of human salt sensitivity: the role of the 11 beta-hydroxysteroid dehydrogenase type 2. J Clin Endocrinol Metab 1999; 84:3745-3749.
44. Agarwal AK, Giacchetti G, Lavery G, Nikkila H, Palermo M, Ricketts M, et al. CA-repeat polymorphism in intron 1 of HSD11B2: effects on gene expression and salt sensitivity. Hypertension 2000; 36:187-194.
45. Johnson AG, Nguyen TV, Davis D. Blood pressure is linked to salt intake and modulated by the angiotensinogen gene in normotensive and hypertensive elderly subjects. J Hypertens 2001; 19:1053-1060.
46. Hunt SC, Geleijnse JM, Wu LL, Witteman JC, Williams RR, Grobbee DE. Enhanced blood pressure response to mild sodium reduction in subjects with the 235T variant of the angiotensinogen gene. Am J Hypertens 1999; 12:460-466.
47. Schorr U, Blaschke K, Beige J, Distler A, Sharma AM. Angiotensinogen M235T variant and salt sensitivity in young normotensive Caucasians. J Hypertens 1999; 17:475-479.
48. Hunt SC, Cook NR, Oberman A, Cutler JA, Hennekens CH, Allender PS, et al. Angiotensinogen genotype, sodium reduction, weight loss, and prevention of hypertension: trials of hypertension prevention, phase II. Hypertension 1998; 32:393-401.
49. Giner V, Poch E, Bragulat E, Oriola J, Gonzalez D, Coca A, et al. Renin-angiotensin system genetic polymorphisms and salt sensitivity in essential hypertension. Hypertension 2000; 35:512-517.
50. Schorr U, Blaschke K, Beige J, Distler A, Sharma AM. G-protein beta3 subunit 825T allele and response to dietary salt in normotensive men. J Hypertens 2000; 18:855-859.
51. Turner ST, Schwartz GL, Chapman AB, Boerwinkle E. C825T polymorphism of the G protein β3-subunit and antihypertensive response to a thiazide diuretic. Hypertension 2001; 37:739-743.
52. Kojima S, Inenaga T, Matsuoka H, Kuramochi M, Omae T, Nara Y, et al. The association between salt sensitivity of blood pressure and some polymorphic factors. J Hypertens 1994; 12:797-801.
53. Hiraga H, Oshima T, Watanabe M, Ishida M, Ishida T, Shingu T, et al. Angiotensin I-converting enzyme gene polymorphism and salt sensitivity in essential hypertension. Hypertension 1996; 27:569-572.
54. Dengel DR, Brown MD, Ferrell RE, Supiano MA. Role of angiotensin converting enzyme genotype in sodium sensitivity in older hypertensives. Am J Hypertens 2001; 14:1178-1184.
55. Schwartz GL, Turner ST, Chapman AB, Boerwinkle E. Interacting effects of gender and genotype on blood pressure response to hydrochlorothiazide. Kidney Int 2002; 62:1718-1723.
56. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med 1997; 157:2413-2446.
57. Mason DA, Moore JD, Green SA, Liggett SB. A Gain-of-function polymorphism in a G-protein coupling domain of the human beta 1-adrenergic receptor. J Biol Chem 1999; 274:12670-12674.
58. Sofowora GG, Dishy V, Muszkat M, Xie HG, Kim RB, Harris PA, et al. A common β1-adrenergic receptor polymorphism (Arg389Gly) affects blood pressure response to β-blockade. Clin Pharmacol Ther 2003; 73:366-371.
59. Liu J, Liu ZQ, Tan ZR, Chen XP, Wang LS, Zhou G, et al. Gly389Arg polymorphism of β1-adrenergic receptor is associated with the cardiovascular response to metoprolol. Clin Pharmacol Ther 2003; 74:372-379.
60. Johnson JA, Zineh I, Puckett BJ, McGorray SP, Yarandi HN, Pauly DF. Beta 1-adrenergic receptor polymorphisms and antihypertensive response to metoprolol. Clin Pharmacol Ther 2003; 74:44-52.
61. Karlsson J, Lind L, Hallberg P, Michaelsson K, Kurland L, Kahan T, et al. Beta1-adrenergic receptor gene polymorphisms and response to beta 1-adrenergic receptor blockade in patients with essential hypertension. Clin Cardiol 2004; 27:347-350.
62. O'Shaughnessy KM, Fu B, Dickerson C, Thurston D, Brown MJ. The gain-of-function G389R variant of the beta1-adrenoceptor does not influence blood pressure or heart rate response to beta-blockade in hypertensive subjects. Clin Sci (Lond) 2000; 99:233-238.
63. Filigheddu F, Reid JE, Troffa C, PinnaParpaglia P, Argiolas G, Testa A, et al. Genetic polymorphisms of the beta-adrenergic system: association with essential hypertension and response to beta-blockade. Pharmacogenom J 2004; 4:154-160.
64. Rathz DA, Brown KM, Kramer LA, Liggett SB. Amino acid 49 polymorphisms of the human beta1-adrenergic receptor affect agonist-promoted trafficking. J Cardiovasc Pharmacol 2002; 39:155-160.
65. Jia H, Hingorani AD, Sharma P, Hopper R, Dickerson C, Trutwein D, et al. Association of the G(s)alpha gene with essential hypertension and response to beta-blockade. Hypertension 1999; 34:8-14.
66. Kurland L, Liljedahl U, Karlsson J, Kahan T, Malmqvist K, Melhus H, et al. Angiotensinogen gene polymorphisms: relationship to blood pressure response to antihypertensive treatment. Results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA) trial. Am J Hypertens 2004; 17:8-13.
67. Staessen JA, Kuznetsova T, Wang JG, Emelianov D, Vlietinck R, Fagard R. M235T angiotensinogen gene polymorphism and cardiovascular renal risk. J Hypertens 1999; 17:9-17.
68. Dudley C, Keavney B, Casadei B, Conway J, Bird R, Ratcliffe P. Prediction of patient responses to antihypertensive drugs using genetic polymorphisms: investigation of renin-angiotensin system genes. J Hypertens 1996; 14:259-262.
69. Kurland L, Melhus H, Karlsson J, Kahan T, Malmqvist K, Ohman KP, et al. Angiotensin converting enzyme gene polymorphism predicts blood pressure response to angiotensin II receptor type 1 antagonist treatment in hypertensive patients. J Hypertens 2001; 19:1783-1787.
70. Mokwe E, Ohmit SE, Nasser SA, Shafi T, Saunders E, Crook E, et al. Determinants of blood pressure response to quinapril in black and white hypertensive patients: the Quinapril Titration Interval Management Evaluation Trial. Hypertension 2004; 43:1202-1207.
71. Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 1990; 86:1343-1346.
72. Nakai K, Itoh C, Miura Y, Hotta K, Musha T, Itoh T, et al. Deletion polymorphism of the angiotensin I-converting enzyme gene is associated with serum ACE concentration and increased risk for CAD in the Japanese. Circulation 1994; 90:2199-2202.
73. Chiang FT, Lai ZP, Chern TH, Tseng CD, Hsu KL, Lo HM, et al. Lack of association of the angiotensin converting enzyme gene polymorphism with essential hypertension in a Chinese population. Am J Hypertens 1997; 10:197-201.
74. Bloem U, Manatunga AK, Pratt JH. Racial difference in the relationship of an angiotensin I-converting enzyme gene polymorphism to serum angiotensin I-converting enzyme activity. Hypertension 1996; 27: 62-66.
75. Schmidt S, van Hooft IM, Grobbee DE, Ganten D, Ritz E. Polymorphism of the angiotensin I converting enzyme gene is apparently not related to high blood pressure: Dutch Hypertension and Offspring Study. J Hypertens 1993; 11:345-348.
76. Jeunemaitre X, Lifton RP, Hunt SC, Williams RR, Lalouel JM. Absence of linkage between the angiotensin converting enzyme locus and human essential hypertension. Nat Genet 1992; 1:72-75.
77. Cambien F, Poirier O, Lecerf L, Evans A, Cambou JP, Arveiler D, et al. Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction. Nature 1992; 359:641-644.
78. Sohunkert H, Hense HW, Holmer SR, Stender M, Perz S, Keil U, et al. Association between a deletion polymorphism of the angiotensin-converting-enzyme gene and left ventricular hypertrophy. N Engl J Med 1994; 330:1634-1638.
79. Iwai N, Ohmichi N, Nakamura Y, Kinoshita M. DD genotype of the angiotensin-converting enzyme gene is a risk factor for left ventricular hypertrophy. Circulation 1994; 90:2622-2628.
80. Pontremoli R, Sofia A, Tirotta A, Ravera M, Nicolella C, Viazzi F, et al. The deletion polymorphism of the angiotensin I-converting enzyme gene is associated with target organ damage in essential hypertension. J Am Soc Nephrol 1996; 7:2550-2558.
81. Fernandez-Llama P, Poch E, Oriola J, Botey A, Coll E, Darnell A, et al. Angiotensin converting enzyme gene I/D polymorphism in essential hypertension and nephroangiosclerosis. Kidney Int 1998; 53:1743-1747.
82. Nakano Y, Oshima T, Watanabe M, Matsuura H, Kajiyama G, Kambe M. Angiotensin I-converting enzyme gene polymorphism and acute response to captopril in essential hypertension. Am J Hypertens 1997; 10:1064-1068.
83. Todd GP, Chadwick IG, Higgins KS, Yeo WW, Jackson PR, Ramsay LE. Relation between changes in blood pressure and serum ACE activity after a single dose of enalapril and ACE genotype in healthy subjects. Br J Clin Pharmacol 1995; 39:131-134.
84. Mondorf UF, Russ A, Wiesemann A, Herrero M, Oremek G, Lenz T. Contribution of angiotensin I converting enzyme gene polymorphism and angiotensinogen gene polymorphism to blood pressure regulation in essential hypertension. Am J Hypertens 1998; 11:174-183.
85. Ueda S, Meredith PA, Morton JJ, Connell JMC, Elliott HL ACE (I/D) genotype as a predictor of the magnitude and duration of the response to an ACE inhibitor drug (enalaprilat) in humans. Circulation 1998; 98:2148-2153.
86. Hingorani AD, Jia H, Stevens PA, Hopper R, Dickerson JE, Brown MJ. Renin-angiotensin system gene polymorphisms influence blood pressure and the response to angiotensin converting enzyme inhibition. J Hypertens 1995; 13:1602-1609.
87. Sasaki M, Oki T, Iuchi A, Tabata T, Yamada H, Manabe K, et al. Relationship between the angiotensin converting enzyme gene polymorphism and the effects of enalapril on left ventricular hypertrophy and impaired diastolic filling in essential hypertension: M-mode and pulsed Doppler echocardiographic studies. J Hypertens 1996; 14:1403-1408.
88. Stavroulakis GA, Makris TK, Krespi PG, Hatzizacharias AN, Gialeraki AE, Anastasiadis G, et al. Predicting response to chronic antihypertensive treatment with fosinopril: the role of angiotensin-converting enzyme gene polymorphism. Cardiovasc Drugs Ther 2000; 14:427-432.
89. Ohmichi N, Iwai N, Uchida Y, Shichiri G, Nakamura Y, Kinoshita M. Relationship between the response to the angiotensin converting enzyme inhibitor imidapril and the angiotensin converting enzyme genotype. Am J Hypertens 1997; 10:951-955.
90. Harrap SB, Tzourio C, Cambien F, Poirier O, Raoux S, Chalmers J, et al. The ACE gene I/D polymorphism is not associated with the blood pressure and cardiovascular benefits of ACE inhibition. Hypertension 2003; 42:297-303.
91. Kurland L, Melhus Ha, Karlsson J, Kahan T, Malmqvist K, Ohman P, et al. Aldosterone synthase (CYP11B2) -344 C/T polymorphism is related to antihypertensive response: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) trial. Am J Hypertens 2002; 15:389-393.
92. Ortlepp JR, Hanrath P, Mevissen V, Kiel G, Borggrefe M, Hoffmann R. Variants of the CYP11B2 gene predict response to therapy with candesartan. Eur J Pharmacol 2002; 445:151-152.
93. Brand E, Chatelain N, Mulatero P, Fery I, Curnow K, Jeunemaitre X, et al. Structural analysis and evaluation of the aldosterone synthase gene in hypertension. Hypertension 1998; 32:198-204.
94. Liljedahl U, Karlsson J, Melhus H, Kurland L, Lindersson M, Kahan T, et al. A microarray minisequencing system for pharmacogenetic profiling of antihypertensive drug response. Pharmacogenetics 2003; 13:7-17.
95. Yasar U, Tybring G, Hidestrand M, Oscarson M, Ingelman-Sundberg M, Dahl ML, et al. Role of CYP2C9 polymorphism in losartan oxidation. Drug Metab Dispos 2001; 29:1051-1056.
96. Taavitsainen P, Kiukaanniemi K, Pelkonen O. In vitro inhibition screening of human hepatic P450 enzymes by five angiotensin-II receptor antagonists. Eur J Clin Pharmacol 2000; 56:135-140.
97. Lee CR, Pieper JA, Hinderliter AL, Blaisdell JA, Goldstein JA. Losartan and E3174 pharmacokinetics in cytochrome P450 2C9*1/*1, *1 /*2, and *1 /*3 individuals. Pharmacotherapy 2003; 23:720-725.
98. Sekino K, Kubota T, Okada Y, Yamada Y, Yamamoto K, Horiuchi R. et al. Effect of the single CYP2C9*3 allele on pharmacokinetics and pharmacodynamics of losartan in healthy Japanese subjects. Eur J Clin Pharmacol 2003; 59:589-592.
99. Hallberg P, Karlsson J, Kurland L, Lind L, Kahan T, Malmqvist K, et al. The CYP2C9 genotype predicts the blood pressure response to irbesartan: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA) trial. J Hypertens 2002; 20:2089-2093.
100. Nakagawa K, Ishizaki T. Therapeutic relevance of pharmacogenetic factors in cardiovascular medicine. Pharmacol Ther 2000; 86:1-28.
101. Molden E, Johansen PW, Boe GH, Bergan S, Christensen H, Rugstad HE, et al. Pharmacokinetics of diltiazem and its metabolites in relation to CYP2D6 genotype. Clin Pharmacol Ther 2002; 72:333-342.
102. Krekels MM, Gaillard CA, Viergever PP, Van Es PN, Lavrijssen AT, de Leeuw PW. Natriuretic effect of nitrendipine is preceded by transient systemic and renal hemodynamic effects. Cardiovasc Drugs Ther 1997; 11:33-38.
103. Freely associating. Nat Genet 1999; 22:1-2.
104. Wilkins MR, Roses AD, Clifford CP. Pharmacogenetics and the treatment of cardiovascular disease. Heart 2000; 84:353-354.
105. Haga SB, Burke W. Using pharmacogenetics to improve drug safety and efficacy. JAMA 2004; 291:2869-2871.
106. Tunis SR, Stryer DB, Clancy CM. Practical clinical trials: increasing the value of clinical research for decision making in clinical and health policy. JAMA 2003; 290:1624-1632.
107. Psaty BM, Smith NL, Heckbert SR, Vos HL, Lemaitre RN, Reiner AP, et al. Diuretic therapy, the α-adducin gene variant, and the risk of myocardial infarction or stroke in persons with treated hypertension. JAMA 2002; 287:1680-1689.
108. Bis JC, Smith NL, Psaty BM, Heckbert SR, Edwards KL, Lemaitre RN, et al. Angiotensinogen Met235Thr polymorphism, angiotensin-converting enzyme inhibitor therapy, and the risk of nonfatal stroke or myocardial infarction in hypertensive patients. Am J Hypertens 2003; 16:1011-1017.
109. Arnett DK, Boerwinkle E, Davis BR, Eckfeldt J, Ford CE, Black H. Pharmacogenetic approaches to hypertension therapy: design and rationale for the Genetics of Hypertension Associated Treatment (GenHAT) study. Pharmacogenomics J 2002; 2:309-317.